Chris Baker

Chris is an Investment Principal at LifeArc Ventures, the investment team tasked with driving positive impact for patients and delivering financial returns to sustain LifeArc’s charitable activities. Their new strategy focuses on early-stage investment into innovative therapeutics, medical devices, healthtech and diagnostics companies. They invest in Seed and Series A investment rounds, with significant follow-on investment reserved for successful portfolio companies.

Chris was most recently an Associate at Advent Life Sciences, leading the diligence on a range of therapeutic and medical device opportunities, including those in the gene therapy space. Prior to that, Chris worked for ten years in the University technology transfer sector with UCL Business and Cancer Research Technology. He successfully commercialised a number of oncology and gene and cell therapy opportunities, and in addition, he was involved in executing a number of strategic initiatives such as the CRUK Stratified Medicine Programme and Grand Challenge awards. Chris holds a PhD in Genetics with a focus on oncology from the University of Cambridge.